Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endocrinology | 37 | 2023 | 134 | 13.740 |
Why?
|
| Diabetes Mellitus | 37 | 2025 | 853 | 9.330 |
Why?
|
| Standard of Care | 35 | 2023 | 129 | 3.790 |
Why?
|
| Reference Standards | 35 | 2023 | 236 | 3.780 |
Why?
|
| Societies, Medical | 36 | 2023 | 687 | 3.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 19 | 2024 | 814 | 2.900 |
Why?
|
| Transition to Adult Care | 7 | 2025 | 119 | 1.870 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2023 | 1260 | 1.650 |
Why?
|
| Retinal Diseases | 2 | 2023 | 172 | 0.810 |
Why?
|
| Insulin | 5 | 2022 | 1200 | 0.730 |
Why?
|
| Blood Glucose | 7 | 2023 | 1135 | 0.700 |
Why?
|
| Hypoglycemic Agents | 8 | 2023 | 439 | 0.660 |
Why?
|
| Humans | 60 | 2025 | 124005 | 0.650 |
Why?
|
| Prescription Drugs | 1 | 2020 | 54 | 0.630 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 12 | 0.610 |
Why?
|
| Hyperglycemia | 1 | 2020 | 222 | 0.580 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 257 | 0.550 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 727 | 0.540 |
Why?
|
| Dyslipidemias | 1 | 2018 | 230 | 0.490 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2023 | 120 | 0.430 |
Why?
|
| Adolescent Development | 1 | 2013 | 26 | 0.430 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 1939 | 0.400 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 731 | 0.370 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 659 | 0.370 |
Why?
|
| Adolescent | 18 | 2025 | 19222 | 0.350 |
Why?
|
| Comorbidity | 4 | 2023 | 1527 | 0.340 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2021 | 160 | 0.320 |
Why?
|
| Physicians | 1 | 2015 | 579 | 0.310 |
Why?
|
| Clinical Competence | 1 | 2015 | 991 | 0.300 |
Why?
|
| Young Adult | 11 | 2025 | 8971 | 0.260 |
Why?
|
| Insulin Infusion Systems | 3 | 2020 | 63 | 0.230 |
Why?
|
| Child | 13 | 2024 | 24327 | 0.230 |
Why?
|
| Peer Group | 1 | 2024 | 117 | 0.220 |
Why?
|
| Mentors | 1 | 2024 | 145 | 0.210 |
Why?
|
| Liraglutide | 1 | 2022 | 14 | 0.200 |
Why?
|
| Hospitals | 2 | 2023 | 390 | 0.200 |
Why?
|
| Quality Improvement | 3 | 2023 | 640 | 0.200 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 70 | 0.190 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 63 | 0.190 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 3413 | 0.190 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2023 | 116 | 0.190 |
Why?
|
| Adult | 13 | 2025 | 29292 | 0.180 |
Why?
|
| Health Personnel | 1 | 2024 | 503 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2022 | 434 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 198 | 0.160 |
Why?
|
| Passeriformes | 1 | 2008 | 2 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2021 | 227 | 0.150 |
Why?
|
| Reproductive Health | 1 | 2018 | 42 | 0.150 |
Why?
|
| Spatial Behavior | 1 | 2008 | 15 | 0.150 |
Why?
|
| Exploratory Behavior | 1 | 2008 | 53 | 0.150 |
Why?
|
| Female | 14 | 2024 | 66186 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 279 | 0.140 |
Why?
|
| Pregnancy | 4 | 2023 | 7158 | 0.140 |
Why?
|
| Health Education | 1 | 2018 | 220 | 0.140 |
Why?
|
| Behavior, Animal | 1 | 2008 | 492 | 0.120 |
Why?
|
| Pediatrics | 2 | 2014 | 1157 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1162 | 0.120 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2014 | 30 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 94 | 0.110 |
Why?
|
| Psychology, Adolescent | 1 | 2013 | 32 | 0.110 |
Why?
|
| Obesity | 2 | 2023 | 2256 | 0.110 |
Why?
|
| Puberty | 1 | 2013 | 94 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2013 | 120 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1768 | 0.100 |
Why?
|
| Hypertension | 1 | 2020 | 1316 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 2013 | 168 | 0.100 |
Why?
|
| United States | 4 | 2021 | 10853 | 0.100 |
Why?
|
| Social Support | 1 | 2013 | 329 | 0.090 |
Why?
|
| Male | 9 | 2024 | 60908 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2013 | 315 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 436 | 0.090 |
Why?
|
| Self Care | 2 | 2024 | 208 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1264 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2013 | 770 | 0.070 |
Why?
|
| Aged | 2 | 2023 | 19516 | 0.070 |
Why?
|
| Learning | 2 | 2020 | 360 | 0.060 |
Why?
|
| Registries | 2 | 2021 | 1417 | 0.060 |
Why?
|
| Quality of Life | 2 | 2024 | 1898 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 2805 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 132 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2018 | 12262 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3681 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 17 | 0.050 |
Why?
|
| Off-Label Use | 1 | 2021 | 28 | 0.050 |
Why?
|
| Parity | 1 | 2020 | 78 | 0.040 |
Why?
|
| Biomarkers | 2 | 2021 | 3046 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2020 | 40 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2021 | 13978 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 294 | 0.040 |
Why?
|
| Health Behavior | 1 | 2023 | 381 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2020 | 142 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2023 | 540 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 635 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 1102 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 585 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2020 | 357 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 857 | 0.040 |
Why?
|
| Orientation | 1 | 2008 | 49 | 0.040 |
Why?
|
| Space Perception | 1 | 2008 | 62 | 0.040 |
Why?
|
| Cues | 1 | 2008 | 90 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 865 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2020 | 322 | 0.040 |
Why?
|
| Triglycerides | 1 | 2020 | 572 | 0.040 |
Why?
|
| Glucose | 1 | 2021 | 878 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2023 | 721 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 10239 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 567 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 724 | 0.030 |
Why?
|
| Counseling | 1 | 2016 | 216 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2045 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 2441 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1369 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 5126 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2137 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 840 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3426 | 0.020 |
Why?
|
| Prognosis | 1 | 2021 | 4605 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 632 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 3580 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6278 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8170 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 12437 | 0.020 |
Why?
|
| Animals | 1 | 2008 | 33994 | 0.010 |
Why?
|